Hemab Therapeutics

Coagulation disorder biotech Hemab Therapeutics files for a $100 million IPO IPO Overview Hemab Therapeutics, a Phase 3-ready biotech developing blood coagulation disorder treatments, filed on Friday with the SEC to raise up to $100 million in an initial public... Read more